Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Antiretroviral Therapy-induced Bone Loss is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-naïve Persons with HIV Infection: a Phase IIB Trial.

Ofotokun I, Collins LF, Titanji K, Foster A, Moran CA, Sheth AN, Lahiri CD, Lennox JL, Ward L, Easley KA, Weitzmann MN.

Clin Infect Dis. 2019 Oct 17. pii: ciz1027. doi: 10.1093/cid/ciz1027. [Epub ahead of print]

PMID:
31621838
2.

Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.

Benson CA, Andersen JW, Macatangay BJC, Mailliard RB, Rinaldo CR Jr, Read S, Bozzolo DR, Purdue L, Jennings C, Keefer MC, Glesby M, Tebas P, Russell AF, Martin J, Annunziato P, Popmihajlov Z, Lennox JL.

Clin Infect Dis. 2018 Nov 13;67(11):1712-1719. doi: 10.1093/cid/ciy242.

PMID:
29590326
3.

T-cell receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts.

Titanji K, Vunnava A, Foster A, Sheth AN, Lennox JL, Knezevic A, Shenvi N, Easley KA, Ofotokun I, Weitzmann MN.

AIDS. 2018 Apr 24;32(7):885-894. doi: 10.1097/QAD.0000000000001764.

4.

Measurement of Human Immunodeficiency Virus p24 Antigen in Human Cerebrospinal Fluid With Digital Enzyme-Linked Immunosorbent Assay and Association With Decreased Neuropsychological Performance.

Anderson AM, Tyor WR, Mulligan MJ, Waldrop-Valverde D, Lennox JL, Letendre SL.

Clin Infect Dis. 2018 Jun 18;67(1):137-140. doi: 10.1093/cid/ciy056. Erratum in: Clin Infect Dis. 2018 Sep 28;67(8):1313.

5.

Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.

Anderson AM, Lennox JL, Mulligan MM, Loring DW, Zetterberg H, Blennow K, Kessing C, Koneru R, Easley K, Tyor WR.

J Neurovirol. 2017 Feb;23(1):106-112. doi: 10.1007/s13365-016-0466-z. Epub 2016 Jul 11.

6.

Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment.

Anderson AM, Lennox JL, Nguyen ML, Waldrop-Valverde D, Tyor WR, Loring DW.

J Neurovirol. 2016 Dec;22(6):816-822. Epub 2016 May 31.

7.

A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.

Ofotokun I, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford SE, Sheth AN, Lennox JL, Knezevic A, Ward L, Easley KA, Powers P, Weitzmann MN.

Clin Infect Dis. 2016 Sep 1;63(5):663-671. doi: 10.1093/cid/ciw331. Epub 2016 May 18.

8.

HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States.

Landovitz RJ, Tran TT, Cohn SE, Ofotokun I, Godfrey C, Kuritzkes DR, Lennox JL, Currier JS, Ribaudo HJ.

AIDS Behav. 2016 Dec;20(12):2983-2995.

9.

Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection.

Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, Rogers K, Sheth AN, Lahiri CD, Lennox JL, Weitzmann MN.

AIDS. 2016 Jan 28;30(3):405-14. doi: 10.1097/QAD.0000000000000918.

10.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9. Review.

11.

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.

Vardhanabhuti S, Ribaudo HJ, Landovitz RJ, Ofotokun I, Lennox JL, Currier JS, Olson LM, Haas DW.

Open Forum Infect Dis. 2015 Jul 1;2(3):ofv085. doi: 10.1093/ofid/ofv085. eCollection 2015 Sep.

12.

Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ.

Ann Intern Med. 2015 Mar 17;162(6):461-2. doi: 10.7326/L15-5066-3. No abstract available.

PMID:
25775334
13.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team.

Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12.

14.

Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection.

Titanji K, Vunnava A, Sheth AN, Delille C, Lennox JL, Sanford SE, Foster A, Knezevic A, Easley KA, Weitzmann MN, Ofotokun I.

PLoS Pathog. 2014 Nov 13;10(10):e1004497. doi: 10.1371/journal.ppat.1004497. eCollection 2014 Oct.

15.

Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. No abstract available.

PMID:
25285557
16.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

17.

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC; HIV Medicine Association of the Infectious Diseases Society of America.

Clin Infect Dis. 2014 Nov 1;59(9):e96-138. doi: 10.1093/cid/ciu617. Epub 2014 Sep 17.

18.

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, Ofotokun I.

J Clin Pharmacol. 2014 Sep;54(9):1063-71. doi: 10.1002/jcph.298. Epub 2014 Apr 8.

19.

Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.

Wang K, D'Argenio DZ, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-Wood C, Ofotokun I.

Clin Pharmacokinet. 2014 Apr;53(4):361-71. doi: 10.1007/s40262-013-0122-1.

20.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.

21.

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69.

PMID:
23412015
22.

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.

Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks CB, Eron JJ.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):505-8. doi: 10.1097/QAI.0b013e318285cd33.

23.

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

DeJesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators.

HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228. Erratum in: HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233.

PMID:
22849964
24.

The use of HIV-1 integrase inhibitors in antiretroviral naive patients.

Lennox JL.

Curr Opin HIV AIDS. 2012 Sep;7(5):409-14. doi: 10.1097/COH.0b013e3283562a27. Review.

PMID:
22789985
25.

Female genital tract shedding of CXCR4-tropic HIV Type 1 is associated with a majority population of CXCR4-tropic HIV Type 1 in blood and declining CD4(+) cell counts.

Haaland RE, Sullivan ST, Evans-Strickfaden T, Lennox JL, Hart CE.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1524-32. doi: 10.1089/AID.2012.0004. Epub 2012 Mar 23.

26.
27.

Oral sampling and human papillomavirus genotyping in HIV-infected patients.

Steinau M, Reddy D, Sumbry A, Reznik D, Gunthel CJ, Del Rio C, Lennox JL, Unger ER, Nguyen ML.

J Oral Pathol Med. 2012 Apr;41(4):288-91. doi: 10.1111/j.1600-0714.2011.01093.x. Epub 2011 Nov 15.

PMID:
22082117
28.

Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy.

Greenberg JA, Lennox JL, Martin GS.

J Crit Care. 2012 Feb;27(1):51-7. doi: 10.1016/j.jcrc.2011.08.015. Epub 2011 Oct 26.

29.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators.

Clin Infect Dis. 2011 Oct;53(8):807-16. doi: 10.1093/cid/cir510.

PMID:
21921224
30.

HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum.

Kelley CF, Haaland RE, Patel P, Evans-Strickfaden T, Farshy C, Hanson D, Mayer K, Lennox JL, Brooks JT, Hart CE.

J Infect Dis. 2011 Sep 1;204(5):761-7. doi: 10.1093/infdis/jir400.

31.

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W; National Institutes of Health; Centers for Disease Control and Prevention.

Am J Respir Crit Care Med. 2011 Oct 15;184(8):972-9. doi: 10.1164/rccm.201105-0827WS.

32.

High prevalence of persistent parasitic infections in foreign-born, HIV-infected persons in the United States.

Hochberg NS, Moro RN, Sheth AN, Montgomery SP, Steurer F, McAuliffe IT, Wang YF, Armstrong W, Rivera HN, Lennox JL, Franco-Paredes C.

PLoS Negl Trop Dis. 2011 Apr 12;5(4):e1034. doi: 10.1371/journal.pntd.0001034.

33.

Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

Ofotokun I, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, Long MC, Acosta EP.

J Clin Pharmacol. 2011 Nov;51(11):1539-48. doi: 10.1177/0091270010385118. Epub 2011 Jan 5.

34.

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. Erratum in: J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e120. Dosage error in article text.

35.

Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women.

Kelley CF, Sullivan ST, Lennox JL, Evans-Strickfaden T, Hart CE.

AIDS. 2010 Jun 1;24(9):1361-6. doi: 10.1097/QAD.0b013e3283394f3f.

PMID:
20389234
36.

Culturally-adapted and audio-technology assisted HIV/AIDS awareness and education program in rural Nigeria: a cohort study.

Ofotokun I, Binongo JN, Rosenberg ES, Kane M, Ifland R, Lennox JL, Easley KA.

BMC Int Health Hum Rights. 2010 Feb 2;10:2. doi: 10.1186/1472-698X-10-2.

37.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa.

Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.

38.

Pandemic influenza: implications for programs controlling for HIV infection, tuberculosis, and chronic viral hepatitis.

Heffelfinger JD, Patel P, Brooks JT, Calvet H, Daley CL, Dean HD, Edlin BR, Gensheimer KF, Jereb J, Kent CK, Lennox JL, Louie JK, Lynfield R, Peters PJ, Pinckney L, Spradling P, Voetsch AC, Fiore A.

Am J Public Health. 2009 Oct;99 Suppl 2:S333-9. doi: 10.2105/AJPH.2008.158170.

39.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK investigators.

Lancet. 2009 Sep 5;374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1. Epub 2009 Aug 3. Erratum in: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054. Lancet. 2009 Sep 5;374(9692):786.

PMID:
19647866
40.

Antiretroviral therapy: when to start and which drugs to use.

Anderson AM, Lennox JL.

Curr Infect Dis Rep. 2008 Jul;10(4):332-9.

PMID:
18765108
41.

Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, Wehbi M, Freeman GJ, Lennox JL, Workowski KA, Hanson HL, Grakoui A.

J Virol. 2008 Oct;82(20):9808-22. doi: 10.1128/JVI.01075-08. Epub 2008 Jul 30.

42.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.

43.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.

44.

Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.

Ofotokun I, Acosta EP, Lennox JL, Pan Y, Easley KA.

Pharmacotherapy. 2008 Jan;28(1):74-81.

45.
46.

Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.

Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP.

J Clin Pharmacol. 2007 Aug;47(8):970-7. Epub 2007 Jul 5.

47.

Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.

Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R.

HIV Clin Trials. 2007 Mar-Apr;8(2):86-97.

PMID:
17507324
48.

A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis.

Peters PJ, Harrison T, Lennox JL.

Lancet Infect Dis. 2006 Nov;6(11):742-8. Review.

PMID:
17067923
49.

Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load.

Cummins JE, Christensen L, Lennox JL, Bush TJ, Wu Z, Malamud D, Evans-Strickfaden T, Siddig A, Caliendo AM, Hart CE, Dezzutti CS.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):788-95.

PMID:
16910835
50.

Supplemental Content

Loading ...
Support Center